title: Effect of diltiazem slow-release formulation on silent myocardial ischemia in stable coronary artery disease. The Canadian Multicenter Diltiazem Study Group.
abstract: Silent myocardial ischemia is associated with adverse outcome in several subsets of coronary artery disease patients. This article presents results of a placebo-controlled, randomized, double-blind study of the effects of sustained-release diltiazem (180 mg twice daily) on ischemic episodes in 60 patients with documented coronary artery disease. The mean age of the study population was 60 years and 93% were male. The mean number of episodes of silent ischemia per patient was 5.6 (placebo) and 2.8 (diltiazem), a 50% reduction (p less than 0.0001). Duration of ST-segment depression was 119 minutes (placebo) and 67 minutes (diltiazem), a 44% reduction (p less than 0.001). This study demonstrates that sustained-release diltiazem can significantly reduce the frequency and total duration of silent ischemic episodes.
authors.affiliation: Department of Medicine, Montreal Heart Institute, Quebec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Juneau
authors.forename: P
authors.initials: P
authors.lastname: Théroux
authors.forename: D
authors.initials: D
authors.lastname: Waters
mesh_terms: D000328:Adult; D000368:Aged; D002940:Circadian Rhythm; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D005080:Exercise Test / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography
chemical_list: D003692:Delayed-Action Preparations; D004110:Diltiazem